Fabrizio Fabrizi1,2, Simona Verdesca3, Piergiorgio Messa3, Paul Martin4. 1. Division of Nephrology, Maggiore Hospital, IRCCS Foundation, Pad. Croff, via Commenda 15, 20122, Milan, Italy. fabrizi@policlinico.mi.it. 2. Division of Hepatology, University School of Medicine, Miami, FL, USA. fabrizi@policlinico.mi.it. 3. Division of Nephrology, Maggiore Hospital, IRCCS Foundation, Pad. Croff, via Commenda 15, 20122, Milan, Italy. 4. Division of Hepatology, University School of Medicine, Miami, FL, USA.
Abstract
BACKGROUND AND RATIONALE: Chronic kidney disease and hepatitis C virus are prevalent in the general population worldwide, and controversy exists about the impact of HCV infection on the development and progression of kidney disease. DESIGN: A systematic review of the published medical literature was made to assess whether positive anti-HCV serologic status plays an independent impact on the development of chronic kidney disease in the adult general population. We used a random-effects model to generate a summary estimate of the relative risk of chronic kidney disease (defined by reduced glomerular filtration rate or detectable proteinuria) with HCV across the published studies. Meta-regression and stratified analysis were also conducted. RESULTS: Twenty-three studies (n = 2,842,421 patients) were eligible, and separate meta-analyses were performed according to the outcome. Pooling results of longitudinal studies (n = 9; 1,947,034 unique patients) demonstrated a relationship between positive HCV serologic status and increased incidence of chronic kidney disease, the summary estimate for adjusted hazard ratio was 1.43 (95% confidence interval 1.23; 1.63, P = 0.0001), and between-studies heterogeneity was noted (P value by Q test <0.0001). The risk of the incidence of chronic kidney disease associated with HCV, in the subset of Asian surveys, was 1.31 (95% confidence interval 1.16; 1.45) without heterogeneity (P value by Q test = 0.6). HCV positive serology was an independent risk factor for proteinuria; adjusted odds ratio, 1.508 (95% confidence intervals 1.19; 1.89, P = 0.0001) (n = 6 studies; 107,356 unique patients). CONCLUSIONS: HCV infection is associated with an increased risk of developing chronic kidney disease in the adult general population.
BACKGROUND AND RATIONALE: Chronic kidney disease and hepatitis C virus are prevalent in the general population worldwide, and controversy exists about the impact of HCV infection on the development and progression of kidney disease. DESIGN: A systematic review of the published medical literature was made to assess whether positive anti-HCV serologic status plays an independent impact on the development of chronic kidney disease in the adult general population. We used a random-effects model to generate a summary estimate of the relative risk of chronic kidney disease (defined by reduced glomerular filtration rate or detectable proteinuria) with HCV across the published studies. Meta-regression and stratified analysis were also conducted. RESULTS: Twenty-three studies (n = 2,842,421 patients) were eligible, and separate meta-analyses were performed according to the outcome. Pooling results of longitudinal studies (n = 9; 1,947,034 unique patients) demonstrated a relationship between positive HCV serologic status and increased incidence of chronic kidney disease, the summary estimate for adjusted hazard ratio was 1.43 (95% confidence interval 1.23; 1.63, P = 0.0001), and between-studies heterogeneity was noted (P value by Q test <0.0001). The risk of the incidence of chronic kidney disease associated with HCV, in the subset of Asian surveys, was 1.31 (95% confidence interval 1.16; 1.45) without heterogeneity (P value by Q test = 0.6). HCV positive serology was an independent risk factor for proteinuria; adjusted odds ratio, 1.508 (95% confidence intervals 1.19; 1.89, P = 0.0001) (n = 6 studies; 107,356 unique patients). CONCLUSIONS:HCV infection is associated with an increased risk of developing chronic kidney disease in the adult general population.
Authors: Maria Boddi; Rosanna Abbate; Benedetta Chellini; Betti Giusti; Carlo Giannini; Giovanni Pratesi; Luciana Rossi; Carlo Pratesi; Gian Franco Gensini; Laura Paperetti; Anna Linda Zignego Journal: J Clin Virol Date: 2009-11-05 Impact factor: 3.168
Authors: Lorien S Dalrymple; Thomas Koepsell; Joshua Sampson; Tin Louie; Jason A Dominitz; Bessie Young; Bryan Kestenbaum Journal: Clin J Am Soc Nephrol Date: 2007-05-30 Impact factor: 8.237
Authors: F Wong; J G O'Leary; K R Reddy; G Garcia-Tsao; M B Fallon; S W Biggins; R M Subramanian; P J Thuluvath; P S Kamath; H Patton; B Maliakkal; P Tandon; H Vargas; L Thacker; J S Bajaj Journal: Am J Gastroenterol Date: 2017-04-25 Impact factor: 10.864
Authors: Matthew P Kosloski; Weihan Zhao; Thomas C Marbury; Richard A Preston; Michael G Collins; David Pugatch; Federico Mensa; Jens Kort; Wei Liu Journal: Antimicrob Agents Chemother Date: 2018-02-23 Impact factor: 5.191
Authors: Sara Yee Tartof; Jin-Wen Hsu; Rong Wei; Kevin B Rubenstein; Haihong Hu; Jean Marie Arduino; Michael Horberg; Stephen F Derose; Lei Qian; Carla V Rodriguez Journal: Clin J Am Soc Nephrol Date: 2018-09-21 Impact factor: 8.237
Authors: Georg Dultz; Tobias Müller; Jörg Petersen; Stefan Mauss; Tim Zimmermann; Marion Muche; Karl-Georg Simon; Thomas Berg; Stefan Zeuzem; Dietrich Hüppe; Klaus Böker; Heiner Wedemeyer; Tania M Welzel Journal: Drugs Aging Date: 2018-09 Impact factor: 4.271